Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
10 hedge funds and large institutions have $389K invested in Sonnet BioTherapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 11 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
44% less funds holding
Funds holding: 18 → 10 (-8)
61% less capital invested
Capital invested by funds: $997K → $389K (-$608K)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$89.3K |
| 2 |
Mariner
Overland Park,
Kansas
|
+$44.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$36.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.7K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$5.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$37K |
| 2 |
State Street
Boston,
Massachusetts
|
-$36K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30K |
| 4 |
CAM
Campion Asset Management
Falls Church,
Virginia
|
-$25K |
| 5 |
Renaissance Technologies
New York
|
-$22K |
SONN Hedge Fund Activity: Q3 2022 in Review
10 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2022, worth a combined $389K — down 61% from $997K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SONN and 3 opened new positions — a net loss of 8 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $89.3K. The largest seller was Advisory Services Network, exiting entirely with an estimated $37K sold.
- 10 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2022, down from 18 in Q2 2022.
- Funds reported $389K of Sonnet BioTherapeutics stock for Q3 2022, down 61% quarter-over-quarter.
- 3 funds opened new Sonnet BioTherapeutics positions in Q3 2022 and 11 closed out, a net change of -8 holders.
- The largest Sonnet BioTherapeutics buyer in Q3 2022 was Virtu Financial, an estimated $89.3K added.
- The largest Sonnet BioTherapeutics seller in Q3 2022 was Advisory Services Network, an estimated $37K sold.
Based on aggregated 13F filings for Q3 2022.